The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 30, 2005
Filed:
Jul. 21, 2003
Miljenko Dumić, Zagreb, HR;
Mladen Vinković, {hacek over (C)}akovec, HR;
Marina Oresic, Sesvete, HR;
Ernest Mestrovic, Bjelovar, HR;
Aleksandar Danilovski, Rijeka, HR;
Alojz Dumbovic, Zagreb, HR;
Knezevic Zdravka, Zagreb, HR;
Gorjana Lazarevski, Zagreb, HR;
Darko Filic, Zagreb, HR;
Dominik Cincic, Zagreb, HR;
Katica Lazaric, Zagreb, HR;
Dejan-kresimir Bucar, Pu{hacek over (s)}ća, HR;
Miljenko Dumić, Zagreb, HR;
Mladen Vinković, {hacek over (C)}akovec, HR;
Marina Oresic, Sesvete, HR;
Ernest Mestrovic, Bjelovar, HR;
Aleksandar Danilovski, Rijeka, HR;
Alojz Dumbovic, Zagreb, HR;
Knezevic Zdravka, Zagreb, HR;
Gorjana Lazarevski, Zagreb, HR;
Darko Filic, Zagreb, HR;
Dominik Cincic, Zagreb, HR;
Katica Lazaric, Zagreb, HR;
Dejan-Kresimir Bucar, Pu{hacek over (s)}ća, HR;
Pliva Pharmaceutical Industry, Incorporated, Zagreb, HR;
Abstract
Substantially pure amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A. In addition, this disclosure is directed to a process for the preparation thereof from crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A via orthorhombic isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, of the general formula I:wherein S represents a water-miscible or water-immiscible organic solvent, characterized by the orthorhombic space group P222, with average unit cell parameters a=8.2 to 9.7 Å, b=11.5 to 13.5 Å, c=44.5 to 47.0 Å, α=β=γ=90°, wherein a, b and c represent the crystal axes lengths and α, β and γ represent the angles between the crystal axes. In addition, pharmaceutical compositions containing the substantially pure amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A are disclosed, as well as a method for the treatment of bacterial and protozoal infections, and inflammation related diseases in humans and animals by administration of a pharmaceutical composition containing same.